GWM Advisors LLC reduced its position in Amgen, Inc. (NASDAQ:AMGN) by 7.7% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 11,188 shares of the medical research company’s stock after selling 929 shares during the period. GWM Advisors LLC’s holdings in Amgen were worth $2,021,000 as of its most recent filing with the SEC.
A number of other large investors have also recently modified their holdings of the stock. FMR LLC lifted its position in Amgen by 4.8% during the second quarter. FMR LLC now owns 56,999,572 shares of the medical research company’s stock worth $9,817,037,000 after acquiring an additional 2,587,041 shares during the last quarter. Vanguard Group Inc. lifted its position in Amgen by 0.9% during the second quarter. Vanguard Group Inc. now owns 52,146,935 shares of the medical research company’s stock worth $8,981,266,000 after acquiring an additional 489,720 shares during the last quarter. BlackRock Inc. lifted its position in Amgen by 1.9% during the second quarter. BlackRock Inc. now owns 49,451,203 shares of the medical research company’s stock worth $8,516,980,000 after acquiring an additional 909,689 shares during the last quarter. Bank of New York Mellon Corp lifted its position in Amgen by 1.7% during the third quarter. Bank of New York Mellon Corp now owns 8,166,002 shares of the medical research company’s stock worth $1,522,551,000 after acquiring an additional 140,117 shares during the last quarter. Finally, Nordea Investment Management AB lifted its position in Amgen by 12.9% during the second quarter. Nordea Investment Management AB now owns 7,040,599 shares of the medical research company’s stock worth $1,212,602,000 after acquiring an additional 806,119 shares during the last quarter. Institutional investors and hedge funds own 79.53% of the company’s stock.
AMGN has been the subject of several research reports. BidaskClub upgraded shares of Amgen from a “strong sell” rating to a “sell” rating in a research report on Saturday, December 2nd. Morgan Stanley cut their price objective on shares of Amgen from $204.00 to $196.00 and set an “overweight” rating for the company in a research report on Friday, February 2nd. Vetr upgraded shares of Amgen from a “sell” rating to a “hold” rating and set a $181.60 price objective for the company in a research report on Tuesday, February 27th. Oppenheimer restated a “buy” rating and set a $205.00 price objective on shares of Amgen in a research report on Tuesday, January 30th. Finally, Piper Jaffray restated a “buy” rating on shares of Amgen in a research report on Tuesday, January 2nd. Two equities research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and eleven have given a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average price target of $191.26.
Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Thursday, February 1st. The medical research company reported $2.89 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.03 by ($0.14). The firm had revenue of $5.80 billion during the quarter, compared to the consensus estimate of $5.84 billion. Amgen had a net margin of 8.66% and a return on equity of 30.87%. The business’s revenue was down 2.7% compared to the same quarter last year. During the same period last year, the business earned $2.89 earnings per share. equities analysts predict that Amgen, Inc. will post 13.25 EPS for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 8th. Investors of record on Thursday, May 17th will be paid a $1.32 dividend. The ex-dividend date of this dividend is Wednesday, May 16th. This represents a $5.28 dividend on an annualized basis and a yield of 3.10%. Amgen’s dividend payout ratio (DPR) is 41.97%.
Amgen declared that its Board of Directors has initiated a share repurchase plan on Thursday, February 1st that permits the company to repurchase $10.00 billion in outstanding shares. This repurchase authorization permits the medical research company to repurchase shares of its stock through open market purchases. Shares repurchase plans are typically a sign that the company’s board of directors believes its stock is undervalued.
In related news, EVP Sean E. Harper sold 1,525 shares of Amgen stock in a transaction that occurred on Wednesday, February 14th. The shares were sold at an average price of $174.18, for a total value of $265,624.50. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders sold 4,575 shares of company stock worth $838,064 over the last three months. 0.19% of the stock is currently owned by insiders.
ILLEGAL ACTIVITY NOTICE: “GWM Advisors LLC Sells 929 Shares of Amgen, Inc. (AMGN)” was first posted by WKRB News and is owned by of WKRB News. If you are reading this piece of content on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://www.wkrb13.com/2018/04/01/gwm-advisors-llc-sells-929-shares-of-amgen-inc-amgn.html.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.